NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcino... ( SOPHIA ANTIPOLIS France June 13 /...)

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR

Date:6/13/2008

SOPHIA ANTIPOLIS, France, June 13 /PRNewswire-FirstCall/ --

NicOx S.A. (Euronext Paris: COX) today announced an additional analysis of the blood pressure data from the 301 phase 3 study, showing a statistically significant difference between naproxcinod and naproxen in terms of the mean change from baseline in systolic and diastolic blood pressure at week 13 (p<0.05 for 3 out of 4 comparisons). Commonly used Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as naproxen, have the tendency to raise blood pressure to an extent that may increase the rate of serious cardiovascular adverse events. The new results are being presented today at the 2008 European League Against Rheumatism (EULAR) Congress in Paris. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class, which NicOx is developing for the treatment of the signs and symptoms of osteoarthritis.

Positive top-line efficacy results from the 301 study have been previously announced, showing that both doses of naproxcinod (750 mg and 375 mg bid) were superior to placebo on all three co-primary efficacy endpoints (p<0.001). Patients' blood pressure was also measured in the study, with a well defined standardized approach where investigators took office blood pressure measurements (OBPM) at each patient visit to the clinical site. The OBPM changes from baseline at week 13 were predefined safety endpoints of the study and the statistical analysis announced today was conducted on a post hoc basis.

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "We are very pleased to be presenting these important data from our most advanced CINOD at EULAR. We believe the results of the post hoc statistical analysis on blood pressure are particularly encouraging, as the 301 study was not powered to show a significant difference between naproxcinod and naproxen on this safety en
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
2. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
3. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
6. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
7. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
8. NicOx Naproxcinod ABPM Data Presented at American Heart Association
9. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
10. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
11. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

Post Your Comments:

(Date:11/24/2009)...irstCall/--AnadysPharmaceuticals,Inc.(Nasdaq: ANDS...perJaffrayHealthcareConferenceonTuesday,December1,...gheldatTheNewYorkPalaceHotel.SteveWorland,Ph.D.,Pr...eanoverviewofAnadysanditsclinicaldevelopmentprogra...willbesimultaneouslywebcastandcanbeaccessedontheIn...

(Date:11/24/2009)...e/--Inadditiontofamily,friendsandhealth,cancersurv...anksgivinggratitudelist. ,, "Theyheardthefactsa...Monday,sverdictstotaling$103millionindamagesagains...womennationwidewhohavesuedWyethandPfizerpharmaceut...mpro.Wisneskiandtheothervictimsofhormonetherapyhav...

(Date:11/24/2009)...-Accumetrics,Inc.,aprivately-helddeveloperandmarke...-to-usediagnosticsystemformeasuringanindividual,sr...4;andaspirin),announcedtodaythatTimothyI.Still,Pre...efFinancialOfficerofAccumetrics,willbepresentingac...areConferencebeingheldinNewYorkCityonDecember1-2,2...

Breaking Medicine Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2 Maryland Woman Thankful for Wyeth Verdicts 2 Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference 2 As the Government Continues to Work Toward Health Care Reform Medtipster is Providing a Free Solution to Rising Health Care Costs for Americans Right 52591 1 As the Government Continues to Work Toward Health Care Reform Medtipster is Providing a Free Solution to Rising Health Care Costs for Americans Right 52591 2 Human cells secrete cancer killing protein UK study finds 52589 1 Human cells secrete cancer killing protein UK study finds 52589 2 Bcl6 gene sculpts helper T cell to boost antibody production 52587 1 Bcl6 gene sculpts helper T cell to boost antibody production 52587 2

[0] Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference [0] Maryland Woman Thankful for Wyeth Verdicts [0] Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference

... Supports Replacement of Pap With HPV Test as Fron...hed in the International Journal of,Cancer show th... (HPV) DNA,test are half as likely to develop mode...years as those who get only conventional cytology ...000 women age 35 years and older,and assessed thei...

...ved positive results of nine month,PAINT trials fo...he results unveiled during plenary session o...Sahajanand Medical Technologies,Pvt. Ltd. (SMT), S...,drug-eluting stents, welcomed the positive result...s of PAINT trial (PercutAneous INTervention,with b...

Other Medicine Technology:Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 2 Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 3 Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 4 Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 2 Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents 3

Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents

(Date:11/25/2009)...rovementShownforthe4thStraightYear ,, WASHING...cerAlliance-Georgia(LCA-GA)issuedthe 4thAnnualRepo...ressbeingmadeagainstthislethaldiseaseinthestateofG...heonlynationalorganizationdedicatedexclusivelytopa...forlungcancer. ,, (Logo: http://www.newscom.com...

(Date:11/25/2009)...eat colorectal cancer also can reverse a rare stom...herapy for the disease, researchers at Vanderbilt ...rier,s disease causes thickening of the stomach li...as well as anemia and swelling in the feet and ank... risk for gastric cancer. Previously, the only eff...

(Date:11/25/2009)...ed under the skin kill tumor cells, study finds ,... A cancer vaccine delivered in a fingernail-size i...tudy reports. , The method uses polymer disks, ...tumor-specific antigens and implanted under the sk.... The Harvard University scientists who developed ...

(Date:11/25/2009)... Nationwide Imaging Services, known as one o...diagnostic imaging equipment, now offering a total...ncing options, service and installation with acqui...Technologies of California) , ...wide Imaging Services is proud to announce its acq...

(Date:11/25/2009)... BioSpace.com, the premier resource for life...rd edition of the BioForest™ Hotbed Campaign...d, CO (Vocus) November 25, 2009 -- BioSpace.com, t...nformation, unveiled the third edition of the BioF... ,This regional campaign is a promotional effort h...

Breaking Medicine News(10 mins):Health News:Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer 2 Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2 Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 2 Health News:Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) 3 Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2

[0] Lung Cancer Alliance-Georgia Issues 4th Annual State-Specific Report Card on Lung Cancer [1] Vanderbilt scientists report first effective medical therapy for rare stomach disorder [2] Implantable Cancer Vaccine Shows Promise [0] Nationwide Imaging Services, Inc., Leader In Diagnostic Imaging Equipment, Announces Acquisition Of Kosmic Medical, Inc. (dba Atlas Medical Technologies of California) [1] BioSpace Showcases Leading Life-Science Companies in the Northwest

... Executive-level management f...ts, and enrollment services providers will convene...lizing Structural Change Management for Patient Re...ment from biopharma and device sponsors, CROs, con...

... YORK, Feb. 26, 2009 Forest Laboratories, Inc. (NY... against the Company by the United States was unse...lations of the federal False Claims Act arising fr...lexa for off-label pediatric use, and that Forest ...

...NCETON, N.J., Feb. 25 PharmaNet Development Group...g provider of clinical development services, today...arter ended December 31, 2008, of $1.6 million, or..., , All financial data provided in this press rel...

...rent construction of Voorhees facility already ahe...a Health will seek approval to sell tax exempt bon...ncing Authority (NJHCFFA) on Thursday, February 26...t the Finance Authority,s requirements to receive ...

...onference call on Thursday, February 26, 2009, at ...b. 25 Service Corporation International (NYSE: ...d services, today reported results for the fourth ... end of this press release. The table below summa...

...HINGTON, Feb. 25 Family Research Council commen...etter directed to the White House urging support f...ropriations bills. These riders prohibit tax dolla...rograms. The letter requests that the riders be i...

DIA to host Patient Recruitment and Retention Forum April 20-21, 2009 Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results Virtua Health Takes Next Step for Continuing Hospital Construction Service Corporation International Announces Fourth Quarter 2008 Financial Results and Comments on Outlook for 2009 FRC Commends Effort to Protect Pro-Life Riders, Prevent Taxpayer Funded Abortions

Castroviejo Corneal Scissors

Vitreous Squeeze Action Forceps (Bishop Harmon )

Pierse Type Corneal Forceps

Suturing Forceps (Bishop Harmon or Bonn Style)

Medicine Products:

Castroviejo Corneal Scissors Vitreous Squeeze Action Forceps (Bishop Harmon )Pierse Type Corneal Forceps Suturing Forceps (Bishop Harmon or Bonn Style)

NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcino...( SOPHIA ANTIPOLIS France June 13 /...),Health